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Growing evidence suggests that epigenetic mechanisms like microRNA-mediated
transcriptional regulation contribute to the pathogenesis of parkinsonism. In order to
study the influence of microRNAs (miRNAs), we analyzed the miRNome 2 days prior to
major cell death in α-synuclein-overexpressing Lund human mesencephalic neurons, a
well-established cell model of Parkinson’s disease (PD), by next-generation sequencing.
The expression levels of 23 miRNAs were significantly altered in α-synucleinoverexpressing cells, 11 were down- and 12 upregulated (P < 0.01; non-adjusted). The
in silico analysis of known target genes of these miRNAs was complemented by the
inclusion of a transcriptome dataset (BeadChip) of the same cellular system, revealing
the G0/G1 cell cycle transition to be markedly enriched. Out of 124 KEGG-annotated
cell cycle genes, 15 were present in the miRNA target gene dataset and six G0/G1
cell cycle genes were found to be significantly altered upon α-synuclein overexpression,
with five genes up- (CCND1, CCND2, and CDK4 at P < 0.01; E2F3, MYC at P < 0.05)
and one gene downregulated (CDKN1C at P < 0.001). Additionally, several of these
altered genes are targeted by miRNAs hsa-miR-34a-5p and hsa-miR-34c-5p, which
also modulate α-synuclein expression levels. Functional intervention by siRNA-mediated
knockdown of the cell cycle gene cyclin D1 (CCND1) confirmed that silencing of cell
cycle initiation is able to substantially reduce α-synuclein-mediated cytotoxicity. The
present findings suggest that α-synuclein accumulation induces microRNA-mediated
aberrant cell cycle activation in post-mitotic dopaminergic neurons. Thus, the mitotic cell
cycle pathway at the level of miRNAs might offer interesting novel therapeutic targets
for PD.
Keywords: Parkinson’s disease, alpha-synuclein, microRNA, next-generation sequencing, cell cycle, cyclin D
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αSyn-mediated effects since it represents a phase in which the
cells are challenged with a significant increase of intracellular
αSyn levels, whereas cytotoxicity remains limited.

INTRODUCTION
In recent years, epigenetic regulation by microRNAs (miRNAs)
has been linked to the pathogenesis of Parkinson’s disease
(PD) (Goodall et al., 2013; Singh and Sen, 2017; Goh et al.,
2019; Ravanidis et al., 2020). PD is primarily characterized
by the progressive loss of dopaminergic neurons in distinct
midbrain regions. A neuropathological hallmark of PD is the
formation of intraneuronal protein inclusions, predominantly
comprising the protein α-synuclein (αSyn) (Spillantini et al.,
1997; Lees et al., 2009), which is encoded by the SNCA gene
on chromosome 4. There are different approaches to model
synucleinopathies in vitro. We chose a robust PD model
with adenoviral overexpression of human wild-type αSyn in
post-mitotic Lund human mesencephalic (LUHMES) neurons
(Lotharius et al., 2005; Höllerhage et al., 2014).
Epigenetic mechanisms such as miRNA-mediated regulation
of gene expression have been suggested to be involved in the
etiology of PD (Goh et al., 2019). miRNAs are endogenous
single-stranded non-coding RNAs with a size of ∼23 nucleotides
and known to play a key role as post-transcriptional regulators
through binding to messenger RNAs (mRNA) (He and Hannon,
2004). The diverse roles of miRNAs have been extensively
studied in the context of PD (Goodall et al., 2013; Singh
and Sen, 2017). In fact, several PD-related processes, such
as apoptosis and mitochondrial integrity, have been reported
to be modulated by differential miRNA expression (MinonesMoyano et al., 2011; Wang et al., 2016). Furthermore, the
study of in vitro and in vivo PD models revealed a link
between several miRNAs and PD pathology, such as miR-7
and miR-153 (Je and Kim, 2017; Titze-de-Almeida and Titzede-Almeida, 2018). Both have been shown to regulate SNCA
mRNA and the αSyn protein levels in mouse models of PD
(Junn et al., 2009; Doxakis, 2010). Additionally, the analysis
of miRNA levels in PD patients revealed a clear dysregulation
of several members of the miRNA family let-7, miR-92, and
miR-184 in peripheral blood and in distinct brain regions, e.g.,
the substantia nigra (Martins et al., 2011; Briggs et al., 2015;
Tatura et al., 2016). One single miRNA might regulate the
expression of multiple target genes (Cai et al., 2009). Therefore,
alterations of a few miRNAs can affect a multitude of genes,
thus influencing PD pathology in multiple steps by targeting
different pathways (Martinez and Peplow, 2017). It is currently
unknown whether certain miRNAs are involved in biological
compensation processes at an early stage of αSyn upregulation
and could therefore be used as novel drug targets to attenuate
synucleinopathies.
Adenoviral SNCA overexpression results in increased
intracellular αSyn protein levels and ∼ 50% cytotoxicity levels
at day 6 post transduction in differentiated LUHMES neurons
(Höllerhage et al., 2014; Chakroun et al., 2020). In the present
study, we performed a miRNome-wide screen in SNCAoverexpressing LUHMES neurons at day 4 post transduction and
focused on (1) altered levels of miRNAs and their target genes
and (2) identifying a functional involvement of dysregulated
biological pathways. This time point was chosen to observe
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MATERIALS AND METHODS
Cell Culture
Lund human mesencephalic cells were cultured as described
previously (Höllerhage et al., 2017). Briefly, cells were
plated in T75 flasks (EasYFlasks, Nunclon DELTA, Thermo
Fisher Scientific, Waltham, MA, United States) coated with
50 µg/mL poly-L-ornithine (Sigma-Aldrich, St. Louis, MO,
United States) in DMEM/F12 growth medium (Sigma-Aldrich)
with 1% N2-supplement (Life Technologies, Carlsbad, CA,
United States) and 0.04 µg/mL human basic fibroblast growth
factor (bFGF; PeproTech, Rocky Hill, CT, United States).
Multi-well dishes and flasks (Nunc MicroWell plates, Thermo
Fisher Scientific, Waltham, MA, United States) were coated
with 50 µg/mL poly-L-ornithine (Sigma-Aldrich) at 37◦ C
overnight and washed three times with phosphate-buffered
saline (PBS; LifeTechnologies) followed by coating with 5 µg/mL
fibronectin (Sigma-Aldrich) for 24 h in the incubator (37◦ C,
5% CO2 ). For experiments, cells were plated at a density of
110,000 cells/cm2 in differentiation medium [DMEM/F12
with 1% N2-supplement, 1 µg/mL tetracycline, 0.49 mg/mL
dibutyryl cyclic-AMP (Sigma-Aldrich), and 2 ng/mL human
glial cell-derived neurotrophic factor (GDNF; R&D Systems,
Minneapolis, MN, United States)]. Cells were routinely tested for
mycoplasma contamination.

Virus Transduction
Adenoviral vectors (AV) harboring the complementary DNA
of human wild-type α-synuclein (SNCA) or green fluorescent
protein (GFP) under cytomegalovirus (CMV) promoter and
enhancer (BioFocus DPI, Leiden, Netherlands) were added at a
multiplicity of infection (MOI) of two to LUHMES cells 48 h after
differentiation started (Höllerhage et al., 2017). After 24 h, cells
were washed three times with PBS to remove adenoviral particles.
Fresh differentiation medium was supplemented and cells kept in
culture until readout. The control cells were treated in the same
manner without the addition of virus.

Immunocytochemistry
Cells were plated on 8-well ibidi µ-slides (ibidi, Gräfelfing,
Germany). After 8 days of differentiation, cells were fixated
with 4% PFA, followed by blocking and permeabilization in 5%
horse serum with 0.1% Triton X-100 in PBS. Then, the cells
were incubated with primary antibodies [mouse monoclonal
anti MAP2 (clone AP20, Millipore MAB3418); rabbit anti β-IIItubulin (clone 9F3, Cell signaling #2128)] for 2 h at room
temperature and washed three times with PBS. Incubation
with fluorescently labeled secondary antibodies [anti rabbit
Alexa 594-conjugated (Thermo Scientific), anti mouse Alexa
488-conjugated (Thermo Scientific)], for 1 h, was followed
by 40 ,6-diamidino-2-phenylindole (DAPI) staining. Cells were
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incubated with 1 µg/mL DAPI in PBS for 5 min, and washed
three times with PBS. Images were subsequently taken using
an inverted microscope (DMI6000, Leica Microsystems) using
a 40x objective and the corresponding Leica Software (Leica
microsystems, Wetzlar).

Transcriptome/mRNA Expression
Analysis
Cells were cultured in 10 cm petri dishes until day 6
of differentiation. After washing the cells once with PBS,
500 mL RLT buffer (Qiagen, Hilden, Germany), activated
with β-mercaptoethanol (Sigma-Aldrich) according to the
manufacturer’s instructions, was added to the petri dishes.
Total RNA of three replicates was collected in sterile cryotubes
(Sarstedt, Nümbrecht, Germany) using a cell scraper (Carl
Roth, Karlsruhe, Germany) and stored at −80◦ C until use. The
expression analysis was performed with Illumina HumanHT12_V3 bead chips (Illumina, San Diego, CA, United States). Data
obtained from Illumina HumanHT-12_V3 bead chips (Illumina,
San Diego, CA, United States) measurements was analyzed in
order to detect differentially regulated transcripts. To this end,
the output obtained from the Illumina GenomeStudio Software
(v. 1.0.6) was used as input for further data preprocessing and
differential analyses steps, which were implemented as workflow
within the KNIME analytics platform (1 v3.6.2). However, since
KNIME allows integration of R code, R capabilities (lumi v2.28.0,
affy v1.54.0, genefilter v1.58.1, limma v3.32.10, lumiHumanAll.db
v1.22.0, and lumiHumanIDMapping v1.10.1) were used. All
R packages are available from Bioconductor2 . We used the
lumi package in order to carry out basic preprocessing of
the input data. To this end, the lumiExpresso function of
lumi was used with the following settings: For background
correction the forcePositive method has been applied, quantile
normalization was carried out and log2 transformation was used
for variance stabilization. After data preprocessing, expression
values (features) that did not show enough variation to allow
reliable detection of differential expression have been removed.
Using the nsFilter method of the R package genefilter the
interquartile range (IQR) was used as a measure for dispersion
and the 0.5 quantile of the IQR values has been used as
cutoff for removal of unnecessary features. For each of the
remaining features a two-tailed t-test was performed with the
rowttests function from the genefilter package. In order to
control the rate of type I errors, when conducting multiple
t-tests, the Benjamini–Hochberg method was applied (FDR
controlling). Features with adjusted p values < 0.05 (608 features)
are considered differentially regulated and used for further
analyses. As additional data processing steps several mappings
procedures were carried out in order to annotate the data with
additional information. The R packages lumiHumanAll.db and
lumiHumanIDMapping were used to retrieve both gene symbols
and unique Entrez Gene identifiers (GeneIDs).

Total RNA and miRNA Isolation
On day 4 post transduction, the cells were washed with PBS
once and detached mechanically. After spinning down (300 g
for 5 min at 4◦ C) the biomaterial was briefly stored at −80◦ C
until RNA was isolated. For total RNA extraction the RNeasy
Plus Kit was used strictly according to manufacturer‘s protocol
(Qiagen, Hilden, Germany). In brief, 350 µL of buffer RLT
Plus were added to the collection tube containing the defrosted
biomaterial and subsequently vortexed for 30 s. The transfer
of the lysate to a gDNA eliminator spin column was followed
by centrifugation for 30 s at 8,000 g. The flow-through was
mixed with 350 µL of 70% ethanol (v/v) and transferred to an
RNeasy spin column. After centrifugation for 15 s at 8,000 g,
the column was washed by adding 700 µL of buffer RW1 to
the column, followed by another centrifugation step for 15 s at
8,000 g. Thereafter, the column was washed twice with 500 µL
of buffer RPE by centrifugation at 8,000 g, for 15 s and 2 min,
respectively. After drying the membrane by centrifugation at full
speed for 1 min, the column was placed into a new 1.5 mL
collection tube. RNA was eluted by adding 30 µL of RNase-free
water directly to the spin column membrane and centrifugation
for 1 min at 8,000 g. For miRNA extraction, the miRNeasy
and RNeasy MinElute Cleanup Kits were used according to the
manufacturer‘s protocol (Qiagen) for enrichment of small RNAs
from cultured cells. In brief, 700 µL QIAzol lysis reagent was
added to the collection tube containing the defrosted biomaterial
and homogenized by vortexing for 1 min. After incubation at
room temperature for 5 min, 140 µL of chloroform were added
and the lysate mixed by shaking the collection tube for 15 s,
followed by incubation at room temperature for 3 min. Phase
separation was accomplished by centrifugation for 15 min at
12,000 g at 4◦ C. 350 µL of the upper aqueous phase were
transferred to a new reaction tube before and 525 µL of
ethanol were added. After thorough mixing, 700 µL sample were
transferred to an RNeasy mini column followed by centrifugation
for 15 s at 8,000 g. This step was repeated with the remainder
of the sample. The flow-through was transferred to a 2 mL
collection tube and 500 µL of ethanol were added. Thereafter,
the sample was transferred to an RNeasy MinElute spin column
and centrifuged for 15 s at 8,000 g. This step was repeated with
the remainder of the sample. The column was washed with
500 µL of buffer RPE by centrifugation for 15 s at 8,000 g
and with 500 µL of 80% ethanol (v/v) by centrifugation for
2 min at 8,000 g. To dry the membrane, the column was
centrifuged at full speed for 5 min. Then, the miRNA was
eluted by adding 14 µL of RNase-free water to the spin column
membrane followed by centrifugation for 1 min at full speed.
The concentrations of the isolated miRNA and RNA of each
condition were quantified using a NanoDrop spectrophotometer
(Thermo Fisher). Thereafter, samples were stored at −80◦ C for
further analysis.
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Next Generation Sequencing of Small
RNAs
50 ng of small RNA enriched fractions were converted
into barcoded cDNA libraries using the NEBNext Multiplex
Small RNA Library Prep kit (New England BioLabs, Ipswich,
MA, United States) for next-generation sequencing on the
1
2
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Fisher’s exact test was used to calculate p-values. The GO term
analysis was corrected for a neutral background. Additionally,
the Kyoto Encyclopedia of Genes and Genomes (KEGG) was
used to include genes from cell cycle pathway (hsa0411) in the
overlap analysis.

Illumina platform. The protocol was performed following the
manufacturer’s instruction using the Caliper Sciclone liquid
handler station (Perkin Elmer, Waltham, MA, United States).
Total RNA or small RNA enriched fractions were ligated to
the 30 SR adaptor (1:4 dilution), hybridized to the Reverse
Transcription Primer (1:4 dilution) and ligated to the 50 SR
adaptor (1:4 dilution). Reverse transcription was performed on
the ligated RNA using ProtoScript II Reverse. cDNA libraries
were indexed and amplified using the following conditions:
denaturation for 30 s at 95◦ C, 16 amplification cycles – 15 s
at 95◦ C, 30 s at 62◦ C, 15 s at 70◦ C–and a final extension for
5 min at 70◦ C. Libraries were purified using a QIAquick kit
(Qiagen). Finally, the library size selection was performed using
AMPure XP Beads (Beckman Coulter, Brea, CA, United States)
with 1.3X Beads/DNA ratio for the “1st Bead Selection” and
1.6X Beads/DNA ratio for the “2nd Bead Selection” to obtain
library size distributions in the range of 100–170bp. Library peak
distribution was controlled and the average size was calculated
using 1 µL on the Bioanalyzer High Sensitivity chip (Agilent
Technologies, Santa Clara, CA, United States). The expected
peak for miRNA is 147 bp. The 150 bp peak corresponds to
piRNA. Molarity of the small RNA library was determined using
KAPA Library Quantification Kit (Hoffman-La Roche, Basel,
Switzerland) following the manufacturer’s recommendations.
Sequencing was performed in 6-plex per sequencing lance on a
HiSeq 4000. Bioinformatic analysis was performed with an inhouse developed pipeline. Quality control was performed using
fastqc (V0.11.3), the sequence reads were streamlined using
Trimmomatic (V0.32), with a sequence quality threshold of Q30
and removing short reads (<15 bp). Reads were mapped using
bowtie (V1.1.2) against mature and stem-loop miRNA databases
(miRbase V21) as well as a proprietary in-house developed
database, which takes natural variation of small RNA sequences
into account. The expected peak size of mapped reads of a size
peaking at 22–23 nucleotides was verified. Counts and TPM
of analyzed miRNAs were recorded and filtered for very low
expressed miRNAs (TPM < 10) in all samples. The filtered count
file, with all miRNA with a TPM < 10 removed, was used for the
differential analysis using DESeq2 (V1.6.3) (Love et al., 2014) and
in-house developed R scripts were used to interpret and evaluate
the results. R scripts were used for graphical representations such
as heat maps and volcano plots.

Reverse Transcription and
Semi-Quantitative Real-Time PCR
Gene expression of selected genes was validated using semiquantitative real-time PCR (qRT-PCR) in a Step One Plus
instrument (Thermo Fisher Scientific). 1,000 ng of extracted
RNA of each condition were reverse transcribed using iScriptTM
cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules,
CA, United States) according to the manufacturer’s protocol.
For qRT-PCR analysis, SYBR Green Select qPCR Supermix
(Thermo Fisher Scientific, Waltham, MA, United States), 5 ng
complementary DNA from total RNA, 0.2 µM forward and
reverse primers, and 0.1 µM 5-carboxy-X-rhodamine (passive
references dye) were used. The PCR primer sequences are
given in Supplementary Table 3. PCR was performed using the
following protocol: 2 min at 50◦ C, 2 min at 95◦ C, and 40 cycles
of 15 s at 95◦ C and 60 s at 60◦ C. Melting curves were recorded.
Cycle threshold (CT ) values were set within the exponential phase
of the PCR. The correct size of the respective single amplicons
was assured by agarose gel electrophoresis. Data was normalized
to the four housekeeping genes, ACTB, GAPDH, GPBP1, and
RPL22. Comparative normalized relative quantities (CNRQ)
were used to calculate the relative expression levels using qBase
Plus software (Biogazelle, Zwijnaarde, Belgium). Expression
of miRNA hsa-miR-34c-5p was analyzed by miRCURY LNA
Universal RT microRNA PCR system (Qiagen). RNA enriched
fractions (50 ng) for each sample underwent reverse transcription
according to the manufacturer’s protocol (Qiagen). Primers were
purchased from Qiagen (hsa-miR-34c-5p, ID YP00205659; U6
snRNA, ID YP00203907) and RNU6 was used as a reference
gene for normalization. Results were evaluated by quantitative
real-time PCR (StepOne Plus, Applied Biosystems) and analyzed
using the 2-11CT method as described in the manufacturer’s
manual (Applied Biosystems).

Cytotoxicity Assay
On day 6 or 8 of differentiation, 30 µL of medium of each
well were transferred to a 96 well plate and 70 µL of 80 mM
Tris/HCl/200 mM NaCl (pH 7.2) buffer containing 10 mM
NADH and 100 mM pyruvate (Sigma-Aldrich) was added. In the
assay, lactate dehydrogenase (LDH) converts pyruvate to lactate
by consuming NADH. NADH metabolization is proportional to
LDH in the medium and its absorption at 340 nm was monitored
with a reference measurement at 420 nm (absorption minimum
for NADH) by a spectrophotometer (ClarioStar, BMG labtech,
Ortenburg, Germany).

miRNA Target Prediction and
Overrepresentation Test
Two different online databases were used for identifying target
genes of differentially regulated miRNAs (P < 0.01). 2,458
miRNA targets were predicted using the TargetScan 7.2 software3 .
Additionally, 280 experimentally validated targets were identified
using MiRTarBase 7.0 software4 . For further analysis, a respective
transcriptomic dataset (Padj < 0.05) with 608 differentially
expressed genes was included. Genes that were present in at
least two of the three gene lists were analyzed for enriched
biological processes using PANTHER-GO-Slim version 14.1.

Cell Viability Assay
Calcein acetoxy methylester (-AM) is a cell-permeable dye. It was
used to determine cell viability in 6 and 8 days differentiated cells.
In viable cells, the non-fluorescent calcein-AM is converted to

3

http://www.targetscan.org
4
http://mirtarbase.mbc.nctu.edu.tw
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green-fluorescent calcein by intracellular esterases. The dye was
added into the medium at a 1:1,000 dilution. The reaction plate
was incubated for 30 min at 37◦ C. The medium was replaced
with 50 µL of PBS and the fluorescence intensity measured
at λ = 577/619 nm by a spectrophotometer (ClarioStar, BMG
Labtech, Ortenburg, Germany) using well scan mode with a
9 × 9 matrix.

Small Interfering RNA Treatment With
siPOOLs
Cells were treated with OptiMem medium containing
lipofectamine RNAiMax (Thermo Fisher Scientific) and
siPOOLs (SiTools, Martinsried, Germany) comprising 20
individual small interfering RNAs (siRNAs) harboring different
seeding sequences against a respective mRNA species, thereby
minimizing off-target effects. For the treatment, either 96-well
(100 µL medium) or 6-well (2 mL medium) plates were used. For
each condition, different concentrations of siRNAs were tested
in αSyn-transduced LUHMES neurons. Expression levels of each
target were analyzed with qRT-PCR to determine a working
concentration which leads to comparable silencing efficiency for
cell cycle gene cyclin D1 (CCND1) (50 nM), CCND2 (5 nM) or
both in combination.

Statistical Analysis

FIGURE 1 | Overview of the study workflow. An in vitro SNCA overexpression
model of αSyn-related pathology compared to a GFP-control model served as
basis for the identification and analysis of miRNA target genes.

GraphPad Software Prism 7 (GraphPad Software, La Jolla, CA,
United States) was used for statistical analysis. Each experiment
includes at least three independent repeats. Data are presented as
mean ± standard error of the mean (SEM). Data were generally
compared by ordinary two−way ANOVA with Bonferroni’s or
Sidak’s post hoc test, unless otherwise indicated. If statistically
significant, pairwise comparisons were evaluated by a two-tailed
unpaired t-test.

αSyn adenoviruses (AV) after 2 days in vitro (DIV) and we
determined toxicity, viability and SNCA expression levels at DIV6
and DIV8 days (Figure 2A). A strong SNCA overexpression
[log2 fold change (FC) = 4.83; P < 0.001] was detected by
qRT-PCR 4 days post transduction (DPT; Figure 2B). The
overexpression-induced toxicity, measured by extracellular LDH
activity, significantly increased over time (Figure 2C) and
reached 21.1 ± 0.31% on DIV6 and 46.8 ± 0.20% on DIV8. The
cell viability, measured by the amount of calcein fluorescence,
was significantly decreased in SNCA-overexpressing neurons to
88 ± 2% on DIV6 and to 54 ± 3% on DIV8 (Figure 2D)
in comparison to the respective controls. A disruption of the
cell differentiation process or the presence of non-neuronal cell
populations by SNCA overexpression could be excluded (see
Supplementary Figures 1,2).
In summary, these results confirm the successful adenoviral
SNCA transduction, emerging toxicity and reduced viability
as a measure of αSyn-mediated neurodegeneration at DIV6
(= DPT4). Thus, we used this time point to study the miRNome
in greater detail.

RESULTS
Study Overview
We studied the effect of early phases of αSyn pathology
on the miRNome in a human neuronal cell model using a
hypothesis-free approach. Figure 1 presents an overview of the
analytical process. A miRNome-wide screen was performed in
LUHMES neurons overexpressing either αSyn or GFP 4 days
post transduction. The resulting differentially expressed miRNAs
with significance (P < 0.01) were analyzed further using two
public databases, TargetScan 7.2 and MiRTarBase 7.0. Predicted
and experimentally validated gene targets of the miRNA hits
were compared by an overlap analysis with the respective
transcriptome data set (BeadChip). Genes present in at least
two overlapping entities were used for enrichment analysis. The
most significantly enriched biological process was analyzed by
validation and subsequent siRNA-mediated functional analysis in
the SNCA overexpression model.

miRNome-Wide Screen and Overlap
Analysis With Transcriptome Data
Aberrant miRNA expression of incipient αSyn-mediated
neurodegeneration was studied by a hypothesis-free
comprehensive miRNome-wide approach using next-generation
sequencing at DPT 4. Among 798 detected miRNAs, 55
were found differentially expressed at P < 0.05 including 23

In vitro SNCA Overexpression Model
In order to validate the usability of our in vitro model, we
determined different parameters. Cells were transduced with

Frontiers in Cell and Developmental Biology | www.frontiersin.org

5

March 2021 | Volume 9 | Article 561086

Findeiss et al.

Cell Cycle Involvement in Synucleinopathies

FIGURE 2 | In vitro SNCA overexpression model. (A) In vitro treatment scheme. LUHMES neurons were transduced with adenoviral (AV) vectors of SNCA or GFP
(control virus). DIV, days in vitro; DPT, days post transduction. (B) Expression of SNCA mRNA in LUHMES neurons after 4 days of transduction with GFP AV or
SNCA AV vectors. (C) Cytotoxicity measured by release of lactate dehydrogenase (LDH) at indicated read-out times in untreated cells (control) and cells transduced
with AV GFP (virus control) or AV SNCA. LDH release is expressed as percentage of lysed cells (positive control). (D) Cell viability measured by intracellular hydrolysis
of calcein acetoxy methyl (-AM) ester at indicated read-out times in untreated cells (control) and cells transduced with AV GFP (virus control) or AV SNCA. Data of AV
GFP and AV SNCA were normalized to the respective readout control, set as one. Results are presented as mean ± SEM from at least three biological repeats.
Statistical analysis in panel (B) was Students t-test and in panels (C,D) ordinary two-way ANOVA with Bonferroni’s multiple comparison test. +++ P < 0.001;
*P < 0.05, ***P < 0.001 vs. respective control.

significantly (P < 0.01; non-adjusted) altered compared to GFP
controls. Among the 23 miRNAs with significance (P < 0.01),
11 miRNAs were downregulated and 12 miRNAs upregulated
(Figure 3A; see Supplementary Table 1 for more details). Out
of these 23 miRNAs, 13 were found without prior evidence for
a relation to synucleinopathies while 10 miRNAs had already
been linked to PD (Supplementary Table 1). A comprehensive
in silico analysis of these 23 altered miRNAs was performed using
TargetScan 7.2 and MirTarBase 7.0. A total of 2,458 predicted
and 280 experimentally validated messenger RNAs have been
identified as probable target genes (Figure 3B). According to
MirTarBase 7.0, hsa-miR-34a-5p and hsa-miR-34c-5p directly
target SNCA mRNA. Predicted and experimentally validated
gene targets of 23 significantly altered miRNAs were compared
by an overlap analysis with a respective transcriptome data
set from our cell model that included 608 genes that were
significantly differentially expressed in comparison between
aSyn overexpressing and GFP expressing cells (Padj < 0.05).
We found 154 genes present in at least two of the three
gene lists. Those 154 genes were further tested for enriched
biological processes with PANTHER GO-Slim (Figure 3C;
see Supplementary Table 2 for more details). We discovered
the highest enrichment for the G0/G1 cell cycle regulation of
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cyclin-dependent protein serine/threonine kinase activity (12.44
fold; FDR 3.17E-02) followed by regulation of cell proliferation
(8.36 fold; FDR 1.46E-02), cell proliferation (8.15 fold; 3.58E-02),
positive regulation of signal transduction (7.16 fold; 2.39E-02),
and protein phosphorylation (4.42 fold; 2.49E-03). Within the
highest enriched pathway, we discovered an overrepresentation
of target genes CCND1, CCND2, CCNE2, and CDKN1C involved
in the G0/G1 cell cycle superpathway.

Expression of Cell Cycle Genes Involved
in the G0/G1 Superpathway
According to the KEGG (Kyoto Encyclopedia of Genes
and Genomes) database, CCND1, CCND2, CCNE2, and
CDKN1C are required for the G0/G1 cell cycle transition
(Figure 4A). We compared 124 KEGG-annotated cell cycle
genes with 154 miRNA target genes of our dataset (Figure 4B).
Out of 15 overlapping genes, 10 genes were annotated for
G0/G1 cell cycle phases. We confirmed significant differential
expression levels of six genes in SNCA-overexpressing human
post-mitotic midbrain-derived neurons that are involved
in the G0/G1 cell cycle pathway (Table 1). Five genes were
upregulated: CCND1, CCND2, CDK4, E2F3, MYC; and one
gene was downregulated: CDKN1C. According to MirTarBase,
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FIGURE 3 | miRNome-wide screen and overlap analysis with transcriptome data. (A) Volcano plot shows 796 detected miRNAs in SNCA vs. GFP overexpressing
LUHMES neurons 4 days after adenoviral transduction. 55 miRNAs with P < 0.05 and 23 with P < 0.01 were differentially expressed (non-adjusted p-value).
(B) Identification of 154 overlap genes of predicted miRNA target genes (TargetScan 7.2 database) and experimentally validated target genes (MiRTarBase 7.0
database) with miRNAs of P < 0.01, and significantly regulated mRNAs (Padj < 0.05; Benjamini–Hochberg FDR) from transcriptome analysis (BeadChip).
(C) Overrepresented biological processes identified by PANTHER GO-Slim pathway analysis among 154 overlap genes.

In order to observe effects of αSyn overexpression on the
most upregulated target gene CCND1 (log2 FC = 5.09, P < 0.005),
we monitored the expression levels of SNCA and CCND1

several cell cycle genes are also targeted by hsa-miR-34a-5p
and hsa-miR-34c-5p, which have been shown to directly
target SNCA.
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FIGURE 4 | Cell cycle as most significantly altered process. (A) Simplified illustration of the mitotic cell cycle phases. Encoded proteins of the genes CCND1,
CCND2, CCNE2, and CDKN1C (labeled in blue) from the most significantly enriched process after PANTHER GO-Slim pathway analysis are key players for the
transition of the cell from quiescence to initiation of G1 cell cycle phase. (B) Overlap of 154 target genes predicted by current study and 124 KEGG (Kyoto
Encyclopedia of Genes and Genomes) cell cycle genes identified 15 SNCA overexpression-affected cell cycle genes. Gene expression of SNCA (C), CCND1 (D), and
hsa-miR-34c-5p (E) measured over time by qRT-PCR in LUHMES neurons transduced with adenoviral (AV) vectors of SNCA or GFP (control virus) or non-transduced
(control). Values are related to non-transduced control at the corresponding times set as one. Values in panels (C–E) are mean ± SEM from at least three biological
repeats. Statistical analysis was performed by a two-way ANOVA with Sidak’s correction for multiple comparison testing and, if significant, pairwise comparisons
were evaluated by an unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. GFP virus control in panels (C–E); DIV, days in vitro; DPT, days post transduction.
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DIV3 (Figure 5A). In order to ensure comparable mRNA levels
between the targets, silencing efficiency of siRNA against CCND1
and CCND2 separately and in combination was assessed using
qRT-PCR (Supplementary Figures 4A–C).
On DIV8 (= DPT6), when the viability of SNCAoverexpressing neurons was reduced to ∼50% (Figures 2C,D),
cytotoxicity was analyzed by measuring LDH release
into the medium.
Treatment with 50 nM siRNA directed against CCND1
(1.24 ± 0.02) significantly reduced αSyn-induced toxicity
compared to lipofectamine control (LC) (1.66 ± 0.03; P < 0.0001)
and non-coding (NC) control siRNA (1.60 ± 0.02; P < 0.0001)
(Figure 5B). The CCND2 (1.68 ± 0.03) siRNA treatment at
5 nM did not significantly alter αSyn-induced toxicity in NC
(1.76 ± 0.03; n.s.), only in LC (1.82 ± 0.03; P < 0.0087) control
(Figure 5C). However, the combined application of targeting
siRNAs against CCND1 and CCND2 (1.38 ± 0.03) significantly
decreased toxicity levels under LC (1.62 ± 0.03; P < 0.0001)
and NC (1.61 ± 0.03; P < 0.0001) conditions in SNCA virustransduced cells (Figure 5D). In summary, siRNA silencing
of the top-most upregulated cell cycle gene CCND1 identified
through a comprehensive miRNA screen led to considerable
attenuation of LDH release in SNCA overexpressing post-mitotic
neurons by 38.7%.

TABLE 1 | Gene expression of 10 G0/G1 cell cycle-related genes obtained from
the transcriptome analysis (BeadChip) and validated by qRT-PCR analysis.
Gene

Transcriptome data

qRT-PCR data

Log2 FC

Padj

Log2 FC

P

CCND1*

0.86

0.035

5.09

0.0018

CCND2*

1.98

0.006

2.17

0.0007

CCNE2

n.d.

–

0.08

n.s.

CDK4*

0.51

0.043

1.12

0.0082
n.s.

CDK6

n.d.

–

0.31

CDKN1A, p21

1.35

0.022

0.26

n.s.

CDKN1C, p57

n.d.

–

−0.36

0.0004

E2F3*

0.59

0.042

0.87

0.0121

E2F5

n.d.

–

0.15

n.s.

MYC

0.06

–

0.98

0.012

*significantly altered in both data sets; n.d., not detected; n.s., not significant.

every 24 h, starting from DIV3 until DIV8 (Figures 4C,D
and Supplementary Figures 3A,B). Expectedly, relative quantity
(RQ) of SNCA expression increased significantly stronger
between DIV3 (24.1 RQ ± 1.6 SEM; P = 0.001) and DIV4 (97.9
RQ ± 4.1 SEM; P < 0.001) and decreased thereafter until DIV8
(10.0 RQ ± 0.5 SEM; P < 0.001) in SNCA AV-transduced cells
compared to the GFP AV-transduced controls (Figure 4C and
Supplementary Figure 3A). We found that CCND1 expression
showed a very similar expression curve to SNCA with a most
significant increase between DIV3 (4.9 RQ ± 0.3 SEM; P < 0.001)
and DIV4 (87.4 RQ ± 3.5 SEM; P < 0.001) and a decrease
until DIV8 (10.1 RQ ± 0.5 SEM; P < 0.001) (Figure 4D and
Supplementary Figure 3B).
Within the same time frame, we additionally examined the
expression of SNCA-regulating miRNA hsa-miR-34c-5p which
was significantly upregulated (P < 0.01) in the miRNome-wide
screen on DIV6 (Figure 4E). We found that hsa-miR-34c-5p
expression significantly increased between DIV5 (2.7 RQ ± 0.03
SEM; P = 0.0164) and DIV7 (4.84 RQ ± 0.06 SEM; P < 0.001)
and decreased on DIV8 (3.8 RQ ± 0.9 SEM; P < 0.001) in
AV SNCA samples compared to AV GFP control. While SNCA
expression steadily decreased after peaking on DIV4 (Figure 4C),
hsa-miR-34c-5p expression was significantly upregulated in AV
αSyn-treated cells. In summary, the expression analysis showed
that altered cell cycle gene expression might be correlated with
SNCA overexpression. We also validated the miRNA screening
result for SNCA-regulating miRNA hsa-miR-34c-5p on DIV6
and observed that 1 day after SNCA expression peaked, miRNA
expression was significantly increased.

DISCUSSION
In the present study, we performed a comprehensive miRNomewide screen in human post-mitotic midbrain derived LUHMES
neurons with moderate αSyn-induced cytotoxicity levels. We
discovered a significant differential expression of 23 miRNAs
(P < 0.01; non-adjusted) with 12 miRNAs- so far without–and
11 miRNAs with known relation in the scientific literature to
models for synucleinopathies or PD. By including comprehensive
in silico target gene mining and subsequent bioinformatics
analysis of target genes, we observed an enrichment of the
cell cycle superpathway and confirmed significant differential
expression levels of six cell cycle genes in SNCA-overexpressing
post-mitotic neurons. By looking into the daily evolvement
of the SNCA transcriptional upregulation between DIV3 and
DIV8, we noted a very similar expression curve of CCND1 and
SNCA, whereas the expression of CCND1 was not altered in
GFP expressing control cells. We also validated the upregulation
of SNCA-regulating miRNA hsa-miR-34c-5p in a time-delayed
manner after SNCA expression peaked. Silencing of the two most
upregulated genes CCND1 and CCND2, involved in the G0/G1
cell cycle initiation, revealed that siRNA against CCND1 alone
and in combination with CCND2 markedly reduced cytotoxicity
levels. Taken together, early-stage intracellular accumulation of
αSyn in human mesencephalic post-mitotic neurons (Chakroun
et al., 2020) is accompanied by an altered expression of miRNAs,
leading to an enrichment of G0/G1 cell cycle genes. Among them,
CCND1 seems to be functionally involved in αSyn-mediated cell
death, as shown by siRNA-mediated intervention.
In our robust model for αSyn-mediated pathology, we
found the levels of 23 miRNAs to be significantly altered.

Functional Analysis of Cyclin D1 and D2
Gene Silencing
To test the relevance of upregulated cell cycle genes in αSynmediated toxicity, we proceeded with a functional analysis of
CCND1 and CCND2 using a siRNA approach. As these particular
cell cycle genes were found to be most upregulated upon SNCA
overexpression on DIV6 (= DPT4) in differentiated LUHMES
neurons, we silenced each gene separately and in combination on
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FIGURE 5 | Functional siRNA analysis. (A) Experimental treatment scheme. LUHMES neurons were transduced with adenoviral (AV) vectors of SNCA or GFP
(control virus) and treated with or without siRNAs against CCND1 and/or CCND2. LDH release as measure for cytotoxicity was determined in control 6 days after
transduction. DIV, days in vitro; DPT, days post transduction. (B–D) Quantification of cytotoxicity upon treatment with siCCND1 (B), siCCND2 (C), and
siCCND1 + siCCND2 (D). Experiments in panels (B–D) included lipofectamine controls (LC), non-coding siRNA controls (NC) in parallel to the coding siRNA
treatment. Data was normalized to LC in control cells. Results are presented as mean ± SEM from seven biological repeats. Statistical analysis in panels (B–D) was
performed by a two-way ANOVA with Bonferroni’s correction for multiple testing and, if significant, pairwise comparisons were evaluated by an unpaired t-test.
**P < 0.01, ***P < 0.001; ns, not significant.

prefrontal cortex of PD patients (Sibley et al., 2012; Hoss et al.,
2016). However, some of our findings are not in line with
previously reported data. We report an upregulation of both,
hsa-miR-34a-5p and hsa-miR-34c-5p, which have been shown to
directly modulate SNCA expression in another cell model of PD
(Kabaria et al., 2015). By monitoring the expression of SNCA
and hsa-miR-34c-5p between DIV3 until DIV8, we not only
validated the upregulation found in the miRNA screen but also
showed that hsa-miRNA-34c-5p was significantly upregulated
after maximal SNCA expression was reached on DIV4. While
SNCA expression steadily decreased thereafter, hsa-miRNA-34c5p stayed upregulated until DIV8. Since hsa-miR-34c can inhibit
SNCA expression by targeting its 30 -UTR (Kabaria et al., 2015),
the upregulation of hsa-miR-34c in our study might be a
counter-regulatory measure of the cell to lower the increased
αSyn levels. In postmortem brain tissue of PD patients at a
late disease stage hsa-miR-34c was shown to be downregulated
(Minones-Moyano et al., 2011). This controversial finding could
be explained by the fact that we used a cell model of early αSyn
overload. Therefore, one could speculate that either miR-34c
expression levels might change depending on disease stage and/or

Out of these 23 miRNAs, 12 have not been implicated in
the pathogenesis of synucleinopathies and related models so
far. Interestingly, 11 miRNAs (hsa-miR-27a-5p, hsa-miR-34a5p, hsa-miR-34c-5p, hsa-let-7e-5p, hsa-miR-184, hsa-mir-320c1, hsa-mir-320c-2, hsa-miR-320d-1, hsa-miR-1224-5p; hsa-miR92b-3p; and hsa-miR-887-3p) have already been reported to
undergo dysregulation in PD patients or been linked to either
target SNCA or pathophysiological mechanisms of PD (MinonesMoyano et al., 2011; Sibley et al., 2012; Soreq et al., 2013; Briggs
et al., 2015; Kabaria et al., 2015; Prajapati et al., 2015; Hoss et al.,
2016; Shamsuzzama et al., 2017) (see Supplementary Table 1).
These results substantiate the validity of our model. Our data
is largely confirmed by further studies performed in other PD
models. For instance, in dopaminergic neurons of PD patients,
an upregulation of hsa-miR-27a and hsa-miR-184 was reported
in accordance with our SNCA overexpression PD model (Briggs
et al., 2015). In leukocytes of PD patients, hsa-mir-320c and hsamiR-92b-3p were found to be downregulated similarly to the
results of the present screen (Soreq et al., 2013). Additionally,
we found a downregulation of hsa-miR-1224-5p and hsa-miR887-3p, which have been reported to be downregulated in the
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hsa-miR-34a-5p, hsa-miR-34c-5p, and hsa-miR-92b-3p) had
already been implicated in synucleinopathies (Soreq et al., 2013;
Briggs et al., 2015; Kabaria et al., 2015; Prajapati et al., 2015;
Shamsuzzama et al., 2017). The rest of the miRNAs listed in
Figure 3A had, to our knowledge, not yet been reported in the
context of synucleinopathies. For example, in different cancer
types the let-7 miRNA family alone modulates the abundance
of CCND1, CDK4 as well as MYC (Mitra et al., 2011; Fairchild
et al., 2019). MYC was also reported to regulate the expression
of a number of miRNAs, e.g., hsa-let-7 and hsa-miR-34a (Bueno
and Malumbres, 2011). The complexity of this miRNA-mRNA
network presents a challenge to the interpretation of our study
results. Thus, one could speculate that the differential miRNA
expression pattern we report might not only occur in response
to the αSyn-mediated cell cycle alterations, but also contribute
to these alterations. However, as both hsa-miR-34a-5p and hsamiR-34c-5p not only target SNCA (Kabaria et al., 2015) but also
CCND1 (Sun et al., 2008; Achari et al., 2014), the upregulation
of both miRNAs could be a response to repress the expression
of both. The decreasing expression levels of SNCA and CCND1
after the upregulation of their regulating miRNA hsa-miR-34c5p between DIV5 until DIV8, point toward a counter-regulatory
role of this specific miRNA in our model. Furthermore, due
to the diverse roles of miRNAs in cellular processes, biological
mechanisms apart from cell cycle activation such as the positive
regulation of signal transduction and/or protein phosphorylation
must certainly be considered. Indeed, both processes were
also found to be markedly enriched in our miRNome-wide
screen. As this study did not investigate the immediate effect
of the differentially regulated miRNAs on CCND1 and SNCA
expression, additional functional studies of miRNAs, e.g., hsamiR-34a-5p, hsa-miR-34c-5p, and hsa-let-7e-5p, are required
to unravel their role in αSyn-mediated cell cycle alterations
and cytotoxicity.
However, as our results were obtained in post-mitotic
neurons, additional functions such as stress-related cell cycle
induction should be considered. Upon cellular stress, the
activation of the transcription factor p53 was shown to change
the expression of several genes encoding miRNAs (Olejniczak
et al., 2018). For instance, miRNAs hsa-miR-34a-5p and hsa-miR34c-5p, which were upregulated in our model, were described to
be regulated by p53 in breast cancer cells (Javeri et al., 2013).
It is conceivable that intracellular accumulation of αSyn and
subsequent aggregation might lead to cellular stress and a p53mediated change in miRNA levels. Further studies are needed to
determine possible functional relations and sequence of events of
αSyn, p53 and miRNAs.
Cell cycle activation depends on the delicate balance of
mitogenic factors. Growth factors stimulate the expression of
crucial G1 phase genes, such as CCND1, CCND2, CDK4, which
were upregulated in our model, whereas the cell cycle inhibitor
p57/Kip2 (CDKN1C) was found to be downregulated. During
the G1 phase, cyclin D protein binds to cyclin-dependent
kinases 4 or 6 (CDK4/6) and, through the neutralization of
retinoblastoma protein (Rb), activates E2F transcription factor
which in turn initiates cell cycle progression by regulating the
transcription of S-phase genes (Figure 4; Aktas et al., 1997;
Choi and Anders, 2014). In SNCA-overexpressing neurons, we

are influenced by non-neuronal cell populations, as unsorted
postmortem brain tissues (including glial cells) was used in
the tissue analysis. Furthermore, hsa-let-7 miRNA has been
shown to be upregulated upon oxidative stress in other cell
models of PD (Prajapati et al., 2015; Shamsuzzama et al., 2017),
while we observed a downregulation in our model. This rather
opposite finding could be attributed to the fact that the complex
miRNA expression profile varies depending on the induced stress,
duration and species in different PD models such as human
SHSY-5Y cells and dopaminergic neurons of C. elegans. The
levels of other PD-associated miRNA, such as miR-7, miR-153 or
miR-133b, were not significantly differentially expressed in our
SNCA overexpression model. Since we were modeling an earlystage αSyn-mediated pathology in dopaminergic neurons, those
miRNAs could be either involved at other stages or in other cell
types relevant for the disease or might be model specific.
A single miRNA might affect several different mRNAs
encoding distinct target genes with a tissue specific expression
profile (Halushka et al., 2018). Hence, investigation and
interpretation of miRNA-mRNA interactions remains very
challenging. In our SNCA overexpression model, we identified
cell cycle and proliferation processes to be overrepresented.
αSyn is a key protein in PD pathogenesis, but its physiological
function is still not fully understood. In addition to its presence
at the synapse, αSyn has been confirmed to be localized in the
nucleus (Goncalves and Outeiro, 2013). Due to its DNA-binding
properties, a regulating role in transcription has been suggested
(Martins et al., 2011) which could result in the miRNA and gene
expression alterations observed in our model. Furthermore, in
accordance with our findings, an emerging body of evidence has
linked PD and αSyn to cell cycle processes (Lee et al., 2003;
Höglinger et al., 2007; Ma et al., 2014; Paiva et al., 2017; SampaioMarques et al., 2019). An increased number of proteins associated
with DNA synthesis and cell cycle re-entry was reported in
dopaminergic neurons of postmortem PD brain tissue (Höglinger
et al., 2007). Similar observations were made in cellular and
animal models of PD (Lee et al., 2003; Paiva et al., 2017). The
atypical re-entry of post-mitotic dopaminergic neurons into the
cell cycle is believed to cause apoptosis (Sampaio-Marques et al.,
2019), as well as nuclear accumulation of αSyn in PC12 cells
(Ma et al., 2014). Both of these effects were shown to promote
neurotoxicity through cell cycle activation (Ma et al., 2014).
Therefore, our finding of cell cycle gene alterations and increased
cytotoxicity upon αSyn overload are in accordance with reports
from PD patients and other PD models. Yet, the exact mechanism
leading to a deleterious cell cycle activation remains unknown.
The control of cell proliferation by distinct miRNAs has
predominantly been described in cancer (Lin and Gregory,
2015). Cell cycle-related genes are regulated by several miRNAs,
which were also present in our post-mitotic neuronal cell
model. Out of the 23 significantly altered miRNAs detected
in this study, eight miRNAs (hsa-let-7e-5p, hsa-miR-184,
hsa-miR-34a-5p, hsa-miR-34c-5p, hsa-miR-92b-3p, hsa-miR1246, hsa-miR-143-3p, and hsa-miR-663a) had already been
experimentally validated to regulate cell cycle-related genes
(Hermeking, 2010; Mitra et al., 2011; Wu et al., 2013; Zhang
et al., 2013; Zhen et al., 2013; Chai et al., 2016; Cho et al.,
2016). Interestingly, five of those (hsa-let-7e-5p, hsa-miR-184,
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found an elevated expression of CDK4 as well as one gene
of the E2F family (E2F3; Table 1). The passage of different
cell cycle checkpoints usually prevents uncontrolled activation
of the cell cycle machinery. However, a dysfunction could be
compensated by the induction of apoptosis (Pardee, 1974). In
the developing brain, the balance between cell proliferation and
programmed cell death is crucial for establishing a functional
neural network. Both processes are highly conserved and share
common mediators (Pucci et al., 2000). During maturation, cells
no longer undergo mitosis, become post-mitotic and terminally
differentiated. Therefore, our finding that SNCA overexpression
in post-mitotic neurons leads to altered expression of genes
responsible for cell cycle activation was rather unexpected. As
CCND1 expression in SNCA overexpressing human neurons
over time was similar to SNCA levels and successful silencing
of CCND1 reduced neuronal cell death, a correlation between
aberrant cell cycle entry and αSyn-induced neurodegeneration
might be well indicated in our model. The downstream effects
of aberrant cell cycle activation in post-mitotic neurons resulting
in cell death have already been established in multiple studies
(Freeman et al., 1994; Padmanabhan et al., 1999; Ino and Chiba,
2001; Jordan-Sciutto et al., 2003; Sumrejkanchanakij et al., 2003;
Herrup and Yang, 2007; Höglinger et al., 2007; Pinho et al.,
2019; Sampaio-Marques et al., 2019). Our findings suggest that
miRNA dysregulation upon SNCA overexpression might be a
very upstream activation mechanism for cell cycle re-activation
in post-mitotic neurons. In order to conclusively establish the
functional role of the reported altered miRNAs in the activation
or counter-regulation of the cell cycle machinery, further studies,
such as targeted knockdown of specific miRNAs, will be required.
Apart from its cell cycle regulatory functions, several other
roles of cyclin D should be considered. Cyclin D1 has been
shown to inhibit the mitochondrial metabolism (Sakamaki et al.,
2006). Mitochondrial dysfunction is currently proposed as a
central factor in PD pathogenesis (Franco-Iborra et al., 2016).
Additionally, cyclin D was shown to play a critical role for
chromatin remodeling (Hulit et al., 2004), another epigenetic
mechanism that has been associated with PD pathophysiology
(Labbe et al., 2016). Higher levels of histone acetylation have
been found in PD patients (Park et al., 2016) and inhibition of
histone acetylases was shown to protect against αSyn-induced
toxicity (Kontopoulos et al., 2006). The neuroprotective effect of
CCND1 silencing that we report might be mediated by its role
in chromatin remodeling. As cyclin D governs diverse roles in
the cytoplasm and cell nuclei, further investigations are needed
to determine the exact mechanisms underlying the interplay
between cyclin D and αSyn-mediated pathology.
In conclusion, a miRNome-wide screen at an early time
point of SNCA overexpression in post-mitotic human neurons
resulted in 23 differentially regulated miRNAs, including 13
novel miRNAs in the context of PD. Target gene analysis of the
respective miRNAs revealed an enrichment of cell cycle G0/G1
activation, which we confirmed using qPCR analysis. Silencing
of CCND1 under SNCA overexpression conditions proved to be
protective and significantly reduced neurotoxicity. Altogether,
our findings reveal that targeting miRNA regulation of the cell
cycle pathway in post-mitotic neurons offer a viable therapeutic
approach for PD and eventually other synucleinopathies.
Frontiers in Cell and Developmental Biology | www.frontiersin.org

Notwithstanding, further research is necessary to determine the
exact pathways and mechanisms involved in aberrant cell cycle
re-entry, and to confirm CCND1 and its regulating miRNAs as
novel drug targets to modulate pathophysiology in PD.
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